The Improvement of Low-dose Esketamine on Postoperative Depression in Patients Undergoing Bariatric Surgery With Preoperative Depression (esketamine)

Jilin University

Status and phase

Not yet enrolling

Phase 4

Conditions

Depressed

Bariatric Surgery

Treatments

Drug: Esketamine

Drug: Dexmedetomidine

Study type

Interventional

Funder types

Other

Identifiers

NCT07179913

25K322-001

Details and patient eligibility

About

The aim of this study is to observe the antidepressant effect of low-dose esketamine in obese patients with preoperative depression and seeking bariatric surgery. We speculate that intraoperative infusion and the addition of a small dose of esketamine to the postoperative analgesic pump can help reduce the proportion of patients with depression after surgery, and may further improve postoperative recovery, reduce the use of postoperative opioids, shorten postoperative hospital stay, and improve postoperative quality of life of patients.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥18 years old and <65 years old
Patients with a BMI greater than 35 kg/m^2
Hamilton Depression score ≥7 points
Planned to undergo elective laparoscopic sleeve gastrectomy

Exclusion criteria

ASA ≥ grade IV
Those who have had or are currently suffering from mental disorders other than anxiety and depression, such as schizophrenia, bipolar disorder, organic mental disorders, etc.
Those who are unable to cooperate in completing the scale assessment
Have received ketamine/esketamine treatment, or are allergic to ketamine/esketamine
Clarify ischemic cardiomyopathy or severe liver and kidney dysfunction (Child pugh grade C, CKD stage G5)
People with opioid dependence and those who have been taking various types of painkillers for a long time (more than 3 months)
Participate in other research